High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
6.28M
+23.21%
-0.190
+58.33%
14.43M
+240.66%
-0.185
+23.33%
16.66M
-2.49%
-0.175
+45.83%
Estimates Revision
The market is revising Upward the revenue expectations for AbCellera Biologics Inc. (ABCL) for FY2025, with the revenue forecasts being adjusted by 5.78% over the past three months. During the same period, the stock price has changed by -13.51%.
Revenue Estimates for FY2025
Revise Upward
+5.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+8.3%
In Past 3 Month
Stock Price
Go Down
-13.51%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.650
Low
4.00
Averages
5.50
High
7.00
Current: 3.650
Low
4.00
Averages
5.50
High
7.00
Leerink
Outperform -> Market Perform
downgrade
$4
2025-11-07
Reason
Leerink
Price Target
$4
2025-11-07
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded AbCellera to Market Perform from Outperform with a $4 price target.
BMO Capital
Outperform
maintain
$5 -> $7
2025-08-08
Reason
BMO Capital
Price Target
$5 -> $7
2025-08-08
maintain
Outperform
Reason
BMO Capital raised the firm's price target on AbCellera to $7 from $5 and keeps an Outperform rating on the shares after its Q2 earnings beat. While previous quarters in recent memory have been more challenged for AbCellera as the company has attempted to transition to an internal development clinical biotechnology company, Q2 earnings highlighted positive updates with the addition of '688 as a new development candidate and initial clinical data for '635 expected in mid-2026, the analyst tells investors in a research note.
Leerink
Outperform
initiated
$5
2025-07-07
Reason
Leerink
Price Target
$5
2025-07-07
initiated
Outperform
Reason
Leerink assumed coverage of AbCellera with an Outperform rating and $5 price target. The firm likes AbCellera's pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.
Truist
Buy
downgrade
$28 -> $10
2025-05-16
Reason
Truist
Price Target
$28 -> $10
2025-05-16
downgrade
Buy
Reason
Truist lowered the firm's price target on AbCellera to $10 from $28 and keeps a Buy rating on the shares. The firm has updated its model after the company's Q1 results, though it continues to be positive about AbCellera, highlighting its continued execution of their wholly owned clinical pipeline, and given the company's hybrid business model with a focus shifting towards a clinical stage biotech, Truist is also updating its discount rate to reflect the transition, the analyst tells investors in a research note.
Stifel
Stephen Willey
Buy
downgrade
$10 -> $8
2025-05-09
Reason
Stifel
Stephen Willey
Price Target
$10 -> $8
2025-05-09
downgrade
Buy
Reason
Keybanc
Scott Schoenhaus
Buy
Maintains
$4 → $5
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$4 → $5
2025-04-16
Maintains
Buy
Reason
KeyBanc raised the firm's price target on AbCellera to $5 from $4 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Abcellera Biologics Inc (ABCL.O) is -5.07, compared to its 5-year average forward P/E of 10.71. For a more detailed relative valuation and DCF analysis to assess Abcellera Biologics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
10.71
Current PE
-5.07
Overvalued PE
56.55
Undervalued PE
-35.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
7.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
64.31
Undervalued EV/EBITDA
-48.69
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
29.93
Current PS
0.00
Overvalued PS
46.42
Undervalued PS
13.44
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ABCL News & Events
Events Timeline
(ET)
2025-11-06
16:45:30
AbCellera announces Q3 earnings per share of 19 cents, surpassing consensus estimate of 16 cents.
2025-09-10 (ET)
2025-09-10
09:15:30
AbCellera Names Sarah Noonberg as Chief Medical Officer
2025-08-07 (ET)
2025-08-07
16:48:25
AbCellera reports Q2 EPS (12c), consensus (16c)
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/bfb75eaaaa83527f178b555f174f35cc7747f8a2d08fd2c48cb619fb6f9b5f10.jpg)
Preview
5.0
12-01NASDAQ.COMInsider Buying Update for Monday, December 1: DASH, ABCL
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/00fdf4973f2b6cd4e149d772761f23b4e1d55913d3ab4137f6b7eef8a38e1da3.jpg)
Preview
2.0
11-28NASDAQ.COMBiotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3bcb523816cfe6e18a86affb6335835723762a853226961133de447825e0cafc.jpg)
Preview
9.5
11-10NASDAQ.COMBiotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
Sign Up For More News
People Also Watch
FAQ
What is Abcellera Biologics Inc (ABCL) stock price today?
What is Abcellera Biologics Inc (ABCL)'s business?
What is the price predicton of ABCL Stock?
What is Abcellera Biologics Inc (ABCL)'s revenue for the last quarter?
What is Abcellera Biologics Inc (ABCL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Abcellera Biologics Inc (ABCL)'s fundamentals?
How many employees does Abcellera Biologics Inc (ABCL). have?